Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GOSS
stocks logo

GOSS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.52M
-19.8%
-0.190
+26.67%
5.77M
-41.61%
-0.190
+18.75%
5.78M
-49.73%
-0.172
+1.18%
Estimates Revision
The market is revising Upward the revenue expectations for Gossamer Bio, Inc. (GOSS) for FY2025, with the revenue forecasts being adjusted by 16.47% over the past three months. During the same period, the stock price has changed by 12.93%.
Revenue Estimates for FY2025
Revise Upward
up Image
+16.47%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+11.19%
In Past 3 Month
Stock Price
Go Up
up Image
+12.93%
In Past 3 Month
Wall Street analysts forecast GOSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOSS is 10.80 USD with a low forecast of 8.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast GOSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOSS is 10.80 USD with a low forecast of 8.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.320
sliders
Low
8.00
Averages
10.80
High
15.00
Current: 3.320
sliders
Low
8.00
Averages
10.80
High
15.00
Oppenheimer
Andreas Argyrides
Outperform
maintain
$9 -> $12
2025-11-10
Reason
Oppenheimer
Andreas Argyrides
Price Target
$9 -> $12
2025-11-10
maintain
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on Gossamer Bio to $12 from $9 and keeps an Outperform rating on the shares following quarterly results. Approaching the February 2026 PROSERA topline readout, the firm continues to see success given PROSERA's baseline population and positive Phase 2 TORREY data increasing the likelihood of achieving statistically significant 6MWD. Additionally, the first clinical site from Phase 3 SERANATA/PH-ILD has been activated, with results expected in 2027.
Cantor Fitzgerald
Overweight
maintain
2025-09-11
Reason
Cantor Fitzgerald
Price Target
2025-09-11
maintain
Overweight
Reason
Cantor Fitzgerald came away from last week's conference with reinforced conviction on Gossamer Bio, telling investors in a research note that sentiment is clearly improving ahead of the February 2026 PROSERA readout. The firm, which has an Overweight rating on Gossamer Bio shares, says the market is still mis-pricing seralutinib's odds, even with the recent stock run-up.
UBS
Neutral -> Buy
upgrade
$9
2025-09-10
Reason
UBS
Price Target
$9
2025-09-10
upgrade
Neutral -> Buy
Reason
UBS upgraded Gossamer Bio to Buy from Neutral with a price target of $9, up from $1.25. The firm views the stock's current risk/reward as "compelling" into the Phase 3 pulmonary arterial hypertension data in February 2026. The probability of success is underappreciated and seralutinib offers a "differentiated" mechanism of action with an inhaled route of administration, the analyst tells investors in a research note. UBS believes the novel mechanism has strong rationale from Gleevec data with improved safety from inhaled delivery.
Scotiabank
Outperform
initiated
$11
2025-07-14
Reason
Scotiabank
Price Target
$11
2025-07-14
initiated
Outperform
Reason
Scotiabank initiated coverage of Gossamer Bio with an Outperform rating and $11 price target. The firm likes the company's approach in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Gossamer's lead asset seralutinib could see significant uptake given its novel mechanism of action as an inhaled tyrosine kinase inhibitor, the analyst tells investors in a research note. Scotiabank thinks the therapy to be an adjunct to standard of care.
Goldman Sachs
Paul Choi
Strong Buy
Maintains
$8 → $7
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$8 → $7
2025-04-17
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$10
2025-03-18
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$10
2025-03-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Gossamer Bio Inc (GOSS.O) is -4.55, compared to its 5-year average forward P/E of -2.51. For a more detailed relative valuation and DCF analysis to assess Gossamer Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.51
Current PE
-4.55
Overvalued PE
-1.22
Undervalued PE
-3.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.45
Undervalued EV/EBITDA
-3.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.86
Current PS
0.00
Overvalued PS
108.03
Undervalued PS
-60.30
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 535.94% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GOSS News & Events

Events Timeline

(ET)
2025-11-05
16:05:29
Gossamer Bio Announces Q3 Earnings Per Share of 21 Cents, Exceeding Consensus Estimate of 20 Cents
select
2025-09-25 (ET)
2025-09-25
07:45:20
Gossamer Bio secures option to purchase Respira Therapeutics
select
2025-09-25
07:39:49
Gossamer Bio to purchase Respira Therapeutics through all-stock deal
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-08Newsfilter
Gossamer Bio Reveals Inducement Grant in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • Stock Option Grants: Gossamer Bio's Compensation Committee approved the grant of non-qualified stock option awards to six non-executive employees, allowing them to purchase a total of 378,996 shares of common stock under the 2023 Employment Inducement Incentive Award Plan.

  • Exercise Price and Vesting: The options have an exercise price of $2.37 per share, equal to the stock's closing price on November 5, 2025, and will vest over four years, with 25% vesting after one year and the remainder in monthly installments.

  • Company Focus: Gossamer Bio is a late-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

  • Investor Relations Contact: For further inquiries, investors and media can contact Bryan Giraudo, Chief Operating Officer and Chief Financial Officer of Gossamer Bio, via the provided email address.

[object Object]
Preview
1.0
11-07Newsfilter
Gossamer Bio to Attend Upcoming Investor Conferences

  • Company Overview: Gossamer Bio, Inc. is a late-stage clinical biopharmaceutical company focused on developing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

  • Upcoming Conferences: The company will participate in the UBS Global Healthcare Conference on November 10 and the Guggenheim Securities Healthcare Innovation Conference on November 11, featuring presentations and one-on-one meetings.

  • Location Details: The UBS conference will be held in Palm Beach, FL, while the Guggenheim conference will take place in Boston, MA.

  • Investor Relations Contact: For inquiries, investors and media can contact Bryan Giraudo, Chief Financial Officer & Chief Operating Officer, via the provided email address.

[object Object]
Preview
8.5
10-30WSJ
Software Company Explores IPO Opportunities Amid Shutdown

  • Navan's IPO Plans: Software company Navan is set to debut on the stock market despite a government shutdown affecting other listings.

  • Pricing and Valuation: The company priced its shares at $25, leading to a valuation of approximately $6.2 billion and raising around $923 million for itself and selling shareholders.

  • Regulatory Workaround: Navan's IPO is notable as it is the largest to utilize a workaround provided by the Securities and Exchange Commission amid the current market conditions.

  • Market Context: The ongoing government shutdown has created challenges for new public offerings, making Navan's successful listing particularly significant.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Gossamer Bio Inc (GOSS) stock price today?

The current price of GOSS is 3.32 USD — it has decreased -2.92 % in the last trading day.

arrow icon

What is Gossamer Bio Inc (GOSS)'s business?

Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

arrow icon

What is the price predicton of GOSS Stock?

Wall Street analysts forecast GOSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOSS is 10.80 USD with a low forecast of 8.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Gossamer Bio Inc (GOSS)'s revenue for the last quarter?

Gossamer Bio Inc revenue for the last quarter amounts to 13.29M USD, increased 40.23 % YoY.

arrow icon

What is Gossamer Bio Inc (GOSS)'s earnings per share (EPS) for the last quarter?

Gossamer Bio Inc. EPS for the last quarter amounts to -0.21 USD, increased 50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Gossamer Bio Inc (GOSS)'s fundamentals?

The market is revising Upward the revenue expectations for Gossamer Bio, Inc. (GOSS) for FY2025, with the revenue forecasts being adjusted by 16.47% over the past three months. During the same period, the stock price has changed by 12.93%.
arrow icon

How many employees does Gossamer Bio Inc (GOSS). have?

Gossamer Bio Inc (GOSS) has 144 emplpoyees as of December 05 2025.

arrow icon

What is Gossamer Bio Inc (GOSS) market cap?

Today GOSS has the market capitalization of 768.43M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free